Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171769

Enrollment

200

Registered

2005-09-15

Start date

2005-04-30

Completion date

Unknown

Last updated

2017-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Nonvalvular Atrial Fibrillation

Brief summary

This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation

Interventions

DRUGCertoparin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* persistent AF (electrical cardioversion is planned) * written informed consent

Exclusion criteria

* acute clinical signs of venous thromboembolism * current oral anticoagulation * indication for medical cardioversion

Design outcomes

Primary

Measure	Time frame
Safety measures including reporting of serious adverse events and adverse events, including vascular and neurological events	—

Countries

Germany, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026